- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Aurinia Pharmaceuticals Inc (AUPH)
Aurinia Pharmaceuticals Inc stock price live, this page displays NASDAQ AUPH stock exchange data. View the AUPH premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Aurinia Pharmaceuticals Inc real time stock price chart below.
What Is the Aurinia Pharmaceuticals Inc Stock Price Today?
The Aurinia Pharmaceuticals Inc stock price today is 16,860.
What Is the Stock Symbol for Aurinia Pharmaceuticals Inc?
The stock symbol for Aurinia Pharmaceuticals Inc is "AUPH."
What Stock Exchange Does Aurinia Pharmaceuticals Inc Trade On?
Aurinia Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Aurinia Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Aurinia Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AUPH quote. (ISIN: CA05156V1022)
What Is the Aurinia Pharmaceuticals Inc Stock Price Today?
The Aurinia Pharmaceuticals Inc stock price today is 16,860.
What Is the Stock Symbol for Aurinia Pharmaceuticals Inc?
The stock symbol for Aurinia Pharmaceuticals Inc is "AUPH."
What Stock Exchange Does Aurinia Pharmaceuticals Inc Trade On?
Aurinia Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Aurinia Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Aurinia Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AUPH quote. (ISIN: CA05156V1022)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.810
17.310
52 wk Range
11.885
19.250
Earnings results expected in 5 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.81017.310
52 wk Range
11.88519.250
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AUPH Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
18.000
Upside
+6.76%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Analyst Ratings
5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 18.000
(+6.76% Upside)
Aurinia Pharmaceuticals Inc Earnings Call Summary for Q4/2025
- Q4 EPS of $1.53 vastly exceeded forecast of $0.15 (920% beat); revenue rose 29% YoY to $77.1M, surpassing estimates of $74.41M.
- LUPKYNIS drove 95.7% of revenue; net income surged to $210.8M from $1.4M YoY, boosted by deferred tax asset valuation allowance release.
- Company projects 2026 LUPKYNIS sales of $305-315M (12-16% growth); advancing Aritinercept biologic for autoimmune disease treatment.
- Strong balance sheet with 5.76 current ratio, 80% gross margin, and $45.7M operating cash flow (up 52% YoY); stock rose 3.67% pre-market.
- Key risk: 95.7% revenue concentration in single product exposes company to market shifts, regulatory challenges, and emerging competition.
Last Updated: 2026/02/26, 16:34
Read Full TranscriptEarnings
Latest Release
Aug 06, 2026
EPS / Forecast
0,28 / 0,23
Revenue / Forecast
83,2M / 80,56M
Compare AUPH to Peers and Sector
Metrics to compare | AUPH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAUPHPeersSector | |
|---|---|---|---|---|
P/E Ratio | 7.1x | 18.4x | −0.3x | |
PEG Ratio | 0.02 | −0.01 | 0.00 | |
Price/Book | 3.6x | 4.7x | 2.6x | |
Price / LTM Sales | 7.2x | 5.2x | 2.9x | |
Upside (Analyst Target) | 6.8% | 112.1% | 65.5% | |
Fair Value Upside | Unlock | 16.2% | 9.5% | Unlock |
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Aurinia (AUPH) Stock Price Today?
The Aurinia stock price today is 16,860 USD.
What Stock Exchange Does Aurinia Trade On?
Aurinia is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Aurinia?
The stock symbol for Aurinia is "AUPH."
What Is the Aurinia Market Cap?
As of today, Aurinia market cap is 2,310B USD.
What Is Aurinia's Earnings Per Share (TTM)?
The Aurinia EPS (TTM) is 2,39.
When Is the Next Aurinia Earnings Date?
Aurinia will release its next earnings report on Oct 29, 2026.
From a Technical Analysis Perspective, Is AUPH a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Aurinia Stock Split?
Aurinia has split 1 times.
How Many Employees Does Aurinia Have?
Aurinia has 128 employees.
What is the current trading status of Aurinia (AUPH)?
As of Oct 24, 2026, Aurinia (AUPH) is trading at a price of 16,860 USD, with a previous close of 16,860 USD. The stock has fluctuated within a day range of 16,810 USD to 17,310 USD, while its 52-week range spans from 11,885 USD to 19,250 USD.
What Is Aurinia (AUPH) Price Target According to Analysts?
The average 12-month price target for Aurinia is 18,000 USD, with a high estimate of 21 USD and a low estimate of 16 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +6,76% Upside potential.
What Is the AUPH Premarket Price?
AUPH's last pre-market stock price is 17,130 USD. The pre-market share volume is 1 730,000, and the stock has decreased by -0,200, or -1,150%.
What Is the AUPH After Hours Price?
AUPH's last after hours stock price is 17,195 USD, the stock has decreased by 0,335, or 1,990%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.